TPP1 and neuronal ceroid lipofuscinosis: Currently, the only approved disease‐modifying therapeutic for NCL is an enzyme replacement therapy for CLN2 disease; however, there are several promising candidate therapies currently in clinical trials for several forms of NCL (Liu et al.